UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 107

Sortiert nach

Ipragliflozin and other sodium―glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data

Pharmacology & therapeutics (Oxford), 2013-07, Vol.139 (1), p.51-59

2013

Volltextzugriff (PDF)

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects

Journal of pharmacological sciences, 2016-03, Vol.130 (3), p.159-169

2016

Volltextzugriff (PDF)

Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice

European journal of pharmacology, 2017-08, Vol.809, p.163-171

2017

Volltextzugriff (PDF)

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

European journal of pharmacology, 2013-09, Vol.715 (1-3), p.246-255

2013

Volltextzugriff (PDF)

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

European journal of pharmacology, 2014-03, Vol.727, p.66-74

2014

Volltextzugriff (PDF)

Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats

European journal of pharmacology, 2015-05, Vol.754, p.19-24

2015

Volltextzugriff (PDF)

The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto–Kakizaki Rats

Biological and Pharmaceutical Bulletin, 2017/05/01, Vol.40(5), pp.675-680

2017

Volltextzugriff (PDF)

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice

Journal of pharmacological sciences, 2016-07, Vol.131 (3), p.198-208

2016

Volltextzugriff (PDF)

Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats

Journal of pharmacy and pharmacology, 2014-07, Vol.66 (7), p.975-987

2014

Volltextzugriff (PDF)

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

Naunyn-Schmiedeberg's archives of pharmacology, 2012-04, Vol.385 (4), p.423-436

2012

Volltextzugriff (PDF)

Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin–Nicotinamide-Induced Mildly Diabetic Mice

Journal of Pharmacological Sciences, 2012, Vol.120(1), pp.36-44

2012

Volltextzugriff (PDF)

Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice

Archives of Pharmacal Research, 2016, 39(2), , pp.259-270

2016

Volltextzugriff (PDF)

The Novel Hypoglycemic Agent YM440 Improves Hepatic Insulin Resistance in Obese Zucker Fatty Rats

Journal of Pharmacological Sciences, 2006, Vol.101(4), pp.311-317

2006

Volltextzugriff (PDF)

YM440, a novel hypoglycemic agent, protects against nephropathy in Zucker fatty rats via plasma triglyceride reduction

European journal of pharmacology, 2006-11, Vol.549 (1), p.185-191

2006

Volltextzugriff (PDF)

Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution

European journal of pharmacology, 2018-01, Vol.818, p.545-553

2018

Volltextzugriff (PDF)

Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin^|^ndash;Nicotinamide-Induced Mildly Diabetic Mice

Journal of pharmacological sciences, 2012, Vol.120 (1), p.36-44

2012

Volltextzugriff (PDF)

Safety and Effectiveness Analyses of Dolutegravir/Lamivudine in Patients with HIV: 2-Year Report of Post-Marketing Surveillance in Japan

Advances in therapy, 2023-04, Vol.40 (4), p.1884-1898

2023

Volltextzugriff (PDF)

Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus

Bioorganic & medicinal chemistry, 2012-05, Vol.20 (10), p.3263-3279

2012

Volltextzugriff (PDF)

Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice

Clinical and experimental pharmacology & physiology, 2015-01, Vol.42 (1), p.87-93

2015

Volltextzugriff (PDF)

Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: Discovery of YM543

Bioorganic & medicinal chemistry, 2013-07, Vol.21 (13), p.3934-3948

2013

Volltextzugriff (PDF)

The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice

Metabolism, clinical and experimental, 2000-03, Vol.49 (3), p.411-417

2000

Volltextzugriff (PDF)

Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses

The Journal of pharmacology and experimental therapeutics, 2014-04, Vol.349 (1), p.10

2014

Volltextzugriff (PDF)

Antagonism of peroxisome proliferator-activated receptor γ prevents high-fat diet-induced obesity in vivo

Biochemical pharmacology, 2006-06, Vol.72 (1), p.42-52

2006

Volltextzugriff (PDF)

Effect of YM-126414 on glucose uptake and redistribution of glucose transporter isotype 4 in muscle cells

European journal of pharmacology, 2000-12, Vol.410 (1), p.1-5

2000

Volltextzugriff (PDF)

Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor

Endocrine research, 2013-08, Vol.38 (3), p.168-183

2013

Volltextzugriff (PDF)

1 – 25 von 107

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(103)

Publikationsform

Sprache

Englisch
(99)
Japanisch
(52)

Erscheinungsjahr

n.n

Thema

Science & Technology
(68)
Life Sciences & Biomedicine
(60)
Male
(39)
Animals
(33)
Humans
(29)
Pharmacology & Pharmacy
(28)
Mice
(19)
Hypoglycemic Agents - Pharmacology
(17)
Biological And Medical Sciences
(16)
Female
(15)
Gastroenterology & Hepatology
(15)
Rats
(15)
Hepatitis B
(14)
Medical Sciences
(14)
Diabetes
(13)
Diabetes Mellitus, Type 2 - Drug Therapy
(13)
Medicine
(13)
Middle Aged
(13)
Sodium-Glucose Transporter 2 - Antagonists & Inhibitors
(13)
Glucosides - Pharmacology
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Ipragliflozin and other sodium―glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects

Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats

Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats

The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto–Kakizaki Rats

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice

Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin–Nicotinamide-Induced Mildly Diabetic Mice

Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice

The Novel Hypoglycemic Agent YM440 Improves Hepatic Insulin Resistance in Obese Zucker Fatty Rats

YM440, a novel hypoglycemic agent, protects against nephropathy in Zucker fatty rats via plasma triglyceride reduction

Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution

Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin^|^ndash;Nicotinamide-Induced Mildly Diabetic Mice

Safety and Effectiveness Analyses of Dolutegravir/Lamivudine in Patients with HIV: 2-Year Report of Post-Marketing Surveillance in Japan

Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus

Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice

Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: Discovery of YM543

The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice

Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses

Antagonism of peroxisome proliferator-activated receptor γ prevents high-fat diet-induced obesity in vivo

Effect of YM-126414 on glucose uptake and redistribution of glucose transporter isotype 4 in muscle cells

Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor

Suchergebnisse filtern